Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Learn more about this revolutionary cancer treatment.
Understand the Basics
Find clinical trials that match your diagnosis, stage and treatment history.
Meet the CRI scientists committed to the development of immunotherapy.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3201
(800) 992-2623(212) 832-9376Staff Directory
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab for advanced stomach or gastroesophageal cancer.
The final day of CICON17 explored two newer immunotherapy approaches that reflect broader understanding of tumor-immune interactions the field has come to appreciate.